Lopicast - A Drug to Fight Coronavirus


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Lopicast - A Drug to Fight Coronavirus
Aprazer Healthcare (p) Ltd.is providng Lopicast - a lifesaving drug for coronavirus at affordable prices. Lopicast is having composition of Ritonavir 50 mg & Lopinavir 200 mg which are recommended to use in coronavirus cases

The endemic of coronavirus started from Wuhan city of China and is knocking the doors of different countries of the world. The deadly symptoms of Coronavirus have put many lives at risk in various regions of the world with maximum effect in Asia especially in China. Continuous attempts are been made to find cure for this virus however considering the growing number of cases doctors have decided to look for some unconventional remedies.

Lopinavir Ritonavir A drug developed to cure HIV infections is used in the treatment of Coronavirus cases. Two antiretroviral components lopinavir and ritonavir are protease inhibitors designed to block HIV viral replication. One hypothesis holds that the drugs could do the same with 2019-nCoV (Coronavirus) which is believed to have originated from the Chinese city of Wuhan.

LOPIKASTis a Generic version of Kaletra now recommended as a treatment for pneumonia caused by the new coronavirus known as 2019-nCoV China National Health Commission says in its updated clinical guidance. Wang Guangfa the leader of Peking University First Hospital pulmonary and critical care medicine department contracted the virus as a member of a national expert team dispatched to Wuhan. Lopinavir Ritonavir tabletskilled his disease Wang told state-run China News Service in areport(Chinese) recently.

In India Aprazer Healthcare Private Limited is a pharmaceutical company based at Delhi which is continuously evolving by providing lifesaving drugs at affordable prices. Aprazer Healthcare Private Limited markets LOPIKAST having composition of Ritonavir 50 mg and Lopinavir 200 mg. As this drug is recommended to use in Coronavirus cases the company has started exporting the product to China and other flu-prone regions at economical prices. The company offers reduced prices of this life-saving drug so that it is easily accessible. Announcing the measures taken by Aprazer Healthcare Pvt. Ltd. CEO of the Company Aprazer said At Aprazer our endeavour is to contribute by supplying the LOPIKAST tablets at the all-time low prices.

He further added that This drug at cost-effective prices will prove to be a stronger response to the prevailing crisis. As it a global emergency we have to face it together.Further he states that If a person is suffering from the expected symptoms of Coronavirus must visit doctor immediately. Lopikast shouldn;t be taken without recommendation and prescription of Physician. According to the doctors treating infected patients of Coronavirus the medicine is not a complete cure for the ailment. However after taking the medicine in combination with flu drug and HIV drug to an infected person the symptoms are expected to improve considerably.

Aprazer Healthcare Pvt. Ltd. has already begun to supply LOPIKAST tablets in the hospitals and cure centres across China. Coronavirus outbreak in China is screaming for assistance from all over the world. The sensitive approach of Aprazers is what other companies should replicate as rightly quoted by Mr. Gandhi. Sometimes profit is not a consideration.

Tags : #Coronavirus #Aprazerhealthcare #Lopicast #Healthcare

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026